



MALIN

Interim Results Presentation

For the 6 month period ended 30 June 2019

3 September 2019

Disclaimer

This document is personal to the recipient and has been prepared and issued by Malin Corporation plc (the "Company") incorporated and registered in Ireland under the Irish Companies Acts and is the responsibility of the Company. For the purposes of this notice, this presentation (the "Presentation") shall mean and include the slides, the oral presentation of the slides by the Company, hard copies of this document and any materials distributed at, or in connection with, that oral presentation. The slides are given in conjunction with an oral presentation and should not be taken out of context.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. Any decision to purchase securities of the Company must be made solely on the basis of the information gained from the recipients' own investigations and analysis of the Company. The information in this Presentation is subject to update, revision, and/or amendment without notice. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This Presentation is not a prospectus (or prospectus equivalent document). This Presentation does not contain "Inside Information" as that term is defined in the Market Abuse Regulation.

This Presentation is strictly private and confidential, is being supplied to you solely for your information and may not be copied, further distributed, published or reproduced in whole or in part, or otherwise disclosed. Failure to comply with these restrictions may constitute a violation of applicable securities laws and/or a criminal offence. The content of this Presentation has not been approved

by Euronext Dublin. This Presentation is being communicated for information purposes only.

No representation or warranty, express or implied, is given by or on behalf of the Company or its investee companies or any of such persons' advisors, or any of their respective parent or subsidiary undertakings, the subsidiary undertakings of any such parent undertakings or any of the directors, officers, employees of such person as to the fairness, accuracy or completeness of the contents of this Presentation, for the opinions contained in this Presentation or for any other statement made or purported to be made by any of them, or on behalf of them and no responsibility or liability is accepted by any person for such information or opinions. No person has been authorised to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. The contents of this Presentation are not to be construed as legal, financial or tax advice. No liability is accepted for any such information or opinions by the Company or its investee companies, or any of their respective directors, members, officers, employees, agents or advisers.

Nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. There is no obligation on any person to update this document, correct any inaccuracies which may become apparent or to publicly announce the result of any revision to the statements made herein except to the extent that they would be required to do so under applicable law or regulation. To the extent permitted by law, no responsibility or liability whatsoever is accepted by the Company or its investee companies or any of such persons' directors, officers, employees or affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions contained herein or otherwise arising in connection herewith. Except where otherwise indicated herein, the information

provided in this Presentation is based on matters as they exist as of the date of preparation and not as of any future date.

Certain statements included in this Presentation contain forward-looking information concerning the Company's and its investee companies' strategy, operations, financial performance or condition, outlook, growth opportunities or circumstances in the sectors or markets in which the Company and its investee companies operate. By their nature, forward-looking statements involve uncertainty because they depend on future circumstances, and relate to events, not all of which are within the Company's or its investee companies' control or can be predicted by the Company or by its investee companies. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Actual results could differ materially from those set out in the forward-looking statements. The forward-looking statements made in this Presentation relate only to events as of the date on which the statements are made. Nothing in this Presentation should be construed as a profit forecast and no part of these results constitutes, or shall be taken to constitute, an invitation or inducement to invest in the Company, and must not be relied upon in any way in connection with any investment decision. The Company expressly disclaim any obligation or undertaking to update or revise any forward-looking statement.

Agenda

- 1 Overview & Business Strategy Recap**

- 2 Operational & Financial Update**

- 3 Investee Company Valuations & News Flow**

- 4 Outlook**

- 5 Q&A**

Overview & Business Strategy Recap

Overview of Business Strategy



**Principal focus
on 4 Priority
Assets**



**Support Growth
Potential Assets to
optimal realisation
points**



**Maintain efficient
business
structure**



**Commitment to
return capital to
shareholders
following
significant
realisation events**

Focus on delivering value for shareholders

Overview of Investee Companies

Multiple value inflection points expected over next 12 to 18 months

4
Priority
Assets



7
Growth
Potential
Assets

3 revenue generative assets



2 early-stage assets



1 public equity



Committed to **Shareholder Distributions** following significant capital realisations

Operational & Financial Update

H1 FY2019 Financial Highlights



Malin's IFRS Interim Consolidated Financial Statements include:

Full financial results of investee companies controlled by Malin

Malin's share of the losses of its associate investments

Fair value movements related to other assets held by Malin

Other investee company-related accounting charges and movements



Key H1 FY2019 Financial Highlights:

IPEV fair value of assets: €385 million

Cash: €31 million (30 August 2019: €31 million)

European Investment Bank debt: €55 million

Cash invested in Priority Assets: €6.3 million

Cash operating expenses: €3.3 million
(Forecasted annual cash operating expenses run rate from 2020: ~€4 million)

Investee Company Valuations & News Flow



Summary of IPEV-compliant Fair Value Estimate at 30 June 2019

| Investee company | 30 June 2019 Fair Value €'m | 31 December 2018 Fair Value €'m | Variance* €'m |
|------------------------------|-----------------------------------|---------------------------------------|------------------|
| Poseida | 112.5 | 106.5 | 6.0 |
| Immunocore | 52.8 | 84.7 | (31.9) |
| Kymab | 29.2 | 28.7 | 0.5 |
| Viamet | 79.5 | 78.0 | 1.5 |
| Revenue generative assets | 95.9 | 95.3 | 0.6 |
| Early-stage assets | 8.2 | 7.4 | 0.8 |
| Novan | 6.2 | 1.9 | 4.3 |
| Legacy assets | 0.5 | 1.2 | (0.7) |
| Total | 384.8 | 403.7 | (18.9) |

Fair value of Investee Companies

€385 million


IPEV guidelines are recognised as best practice in the valuation of private companies

Priority Assets

€274 million
IPEV fair value

Growth Potential Assets


€111 million
IPEV fair value



What's in a Share?

Intrinsic Equity Value is arrived at through our estimate of the fair value of our investee companies in accordance with IPEV guidelines adjusted for net debt

€7.90 per Malin share



Management has committed to return capital realised from its assets to shareholders

Clinical Progression & Near-term Milestones for Investee Companies



Recent progress

Progressed Ph.1 study of lead CAR-T program, P-BCMA-101, reporting positive data, having received RMAT & orphan drug designation from US FDA

Advanced late-stage pre-clinical development of other candidates

Closed a \$142m financing round, led by a \$75m equity investment from Novartis

Near-term milestones

Progress potential registrational Ph.2 clinical trial for P-BCMA-101 towards potential BLA filing

File IND for prostate cancer target (P-PSMA-101) and begin Ph.1 trial

File IND for multiple solid tumour indication (P-MUC1C-101)

File IND for allogeneic product candidate (P-BCMA-ALLO1)



Recent progress

Progressed pivotal trial of lead candidate, IMCgp100

Completed co-dev / co-promo deal with Genentech for MAGE-A4 target (\$100m upfront)

Filed IND for MAGE-A4 target & dosed 1st patient in GSK-partnered, NY-ESO, trial

Appointed Dr Bahija Jallal as CEO, Dr David Berman as Head of R&D & Dr Mohammed Dar as CMO

Near-term milestones

Progression of pivotal trial for IMCgp100 in metastatic uveal melanoma towards a potential BLA filing

Dose 1st patient in Ph.1 trial for MAGE-A4 target (Genentech collaboration)

Data from clinical other programs

Additional IND filings

Clinical Progression & Near-term Milestones for Investee Companies



Recent progress

Positive data from Ph.1 study of lead, KY1005 anti-OX40L, & initiated Ph.2a study

Filed IND for KY1044 anti-ICOS candidate

Appointed Simon Sturge as CEO

Filed confidential Form F-1 with SEC relating to proposed IPO

Entered strategic partnership with LifeArc

Continued to expand & advance discovery & preclinical antibody pipeline

Near-term milestones

Complete proposed IPO

Ph.2a data in anti-OX40L atopic dermatitis indication (KY1005)

Expand KY1005 into other anti-inflammatory indications (acute Graft v Host Disease)

Ph.1/2 data in anti-ICOS agonist (advanced solid tumours) indication (KY1044)



Recent progress

Completed structured sale of lead asset, VT-1161, to NovaQuest. Potential of significant & recurring cash flows from milestones & sales royalties

Near-term milestones

Antifungal interest (VT-1161) to advance through Ph.3 trials (funded by NovaQuest)

Growth Potential Assets

Novan: Ph.3 data in molluscum indication (SB206)

Altan: Potential US approval of IV paracetamol product

Xenex: Submission to FDA for approval of robot device

3D4Medical: Revenue growth from annual subs model

Outlook

Driving Scientific Innovation leading to Improved Patient Outcomes

| Investee Company | Indication | Discovery | Preclinical | Phase 1 | Phase 2 or Pivotal* | Phase 3 | Commercial |
|-------------------------|---------------------------|--|-------------|---------|---------------------|---------|------------|
| Growth Potential Assets | Multiple | [Progress bar spanning all stages] | | | | | |
| Viamet | RVVC | [Progress bar spanning Discovery to Phase 3] | | | | | |
| Novan | Molluscum | [Progress bar spanning Discovery to Phase 3] | | | | | |
| Viamet | Onychomycosis | [Progress bar spanning Discovery to Phase 2] | | | | | |
| Poseida | Multiple myeloma (MM) | [Progress bar spanning Discovery to Phase 2] | | | | | |
| Immunocore | Uveal melanoma | [Progress bar spanning Discovery to Phase 2] | | | | | |
| Kymab | Atopic dermatitis | [Progress bar spanning Discovery to Phase 2] | | | | | |
| Immunocore | IMCnyeso | [Progress bar spanning Discovery to Phase 1] | | | | | |
| Immunocore | MAGE-A4 | [Progress bar spanning Discovery to Phase 1] | | | | | |
| Immunocore | Cutaneous melanoma | [Progress bar spanning Discovery to Phase 1] | | | | | |
| Kymab | Solid tumours (anti-ICOS) | [Progress bar spanning Discovery to Phase 1] | | | | | |
| Poseida | Prostate cancer | [Progress bar spanning Discovery to Preclinical] | | | | | |
| Poseida | Allogeneic MM | [Progress bar spanning Discovery to Preclinical] | | | | | |
| Immunocore | Multiple | [Progress bar spanning Discovery to Preclinical] | | | | | |
| Kymab | Multiple | [Progress bar spanning Discovery to Preclinical] | | | | | |
| Poseida | Multiple | [Progress bar spanning Discovery to Preclinical] | | | | | |

Multiple non-disclosed pre-clinical programmes

*Poseida's P-BCMA-101 is enrolling for a potential registrational trial and IMC's IMCgp100 for uveal melanoma is in a pivotal study

Outlook



Several assets with important milestones in the year ahead, which have the potential to create significant value for shareholders



Focus on delivery of this value and committed to returning capital to shareholders



Targeting annual cash operating expenses of ~€4 million from 2020



Efficient business structure

Q&A

How to find out more

Malin Contact



Jessica Bergin
Director of Investor Relations
+353 1 901-5700
investorrelations@malinplc.com

Malin Website



www.malinplc.com



MALIN

Thank you

malinplc.com